This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belley, A.
Right arrow Articles by Moeck, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belley, A.
Right arrow Articles by Moeck, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2008, p. 3820-3822, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00361-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus{triangledown}

Adam Belley, Eve Neesham-Grenon, Francis F. Arhin, Geoffrey A. McKay, Thomas R. Parr Jr., and Gregory Moeck*

Targanta Therapeutics Incorporated, 7170 Frederick Banting, St. Laurent, Quebec, Canada H4S 2A1

Received 14 March 2008/ Returned for modification 2 May 2008/ Accepted 11 July 2008

Oritavancin is a semisynthetic lipoglycopeptide in clinical development for serious gram-positive infections. This study describes the synergistic activity of oritavancin in combination with gentamicin, linezolid, moxifloxacin, or rifampin in time-kill studies against methicillin-susceptible, vancomycin-intermediate, and vancomycin-resistant Staphylococcus aureus.

* Corresponding author. Mailing address: Targanta Therapeutics Incorporated, 7170 Frederick Banting, St. Laurent, Quebec, Canada H4S 2A1. Phone: (514) 332-1008, ext. 232. Fax: (514) 332-6033. E-mail: gmoeck{at}targanta.com

{triangledown} Published ahead of print on 21 July 2008.

Antimicrobial Agents and Chemotherapy, October 2008, p. 3820-3822, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00361-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • McKay, G. A., Beaulieu, S., Arhin, F. F., Belley, A., Sarmiento, I., Parr, T. Jr, Moeck, G. (2009). Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 63: 1191-1199 [Abstract] [Full Text]  
  • Nguyen, H. A., Denis, O., Vergison, A., Tulkens, P. M., Struelens, M. J., Van Bambeke, F. (2009). Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations. Antimicrob. Agents Chemother. 53: 1443-1449 [Abstract] [Full Text]  
  • Belley, A., Neesham-Grenon, E., McKay, G., Arhin, F. F., Harris, R., Beveridge, T., Parr, T. R. Jr., Moeck, G. (2009). Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro. Antimicrob. Agents Chemother. 53: 918-925 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»